We propose that the lack of co-mutations in MAPK-activating oncogenic drivers, including those involving RAF, RAS, and NF1, and prior studies characterizing particular functional subtypes of MAP2K1 mutation, support MAP2K1 in-frame deletions as defining for a distinct subgroup of melanomas, with potential therapeutic implications. Here, MAP2K1 is linked to melanoma.